RVNC Stock Recent News
RVNC LATEST HEADLINES
NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) of a class action securities lawsuit.
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Revance Therapeutics Inc ("RVNC" or the "Company") (NASDAQ:RVNC) Stock purchased prior to August 11, 2024. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Revance by Crown Laboratories, Inc. ("Crown").
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=131288&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=131160&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").
NEW YORK , Feb. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Revance investors who were adversely affected by alleged securities fraud between February 29, 2024 and December 6, 2024.
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=131082&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP notifies investors of the approaching March 4, 2025, deadline to seek the role of lead plaintiff in a federal securities class action filed on behalf of those who acquired Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ:RVNC) securities between February 29, 2024, through December 6, 2024 (“the Class Period”).
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Revance Therapeutics Inc ("RVNC" or the "Company") (NASDAQ:RVNC) Stock purchased prior to August 11, 2024. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Revance by Crown Laboratories, Inc. ("Crown").
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC).